CRYSTAL LAKE, Ill.— Aptar Digital Health announced encouraging findings from the SPEED1 survey, highlighting the positive impact of its iPUMP® connected assistant on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). The results will be presented at the Congrès Francophone d’Allergologie (CFA) in Paris, running April 15–18, 2025.
According to the survey, iPUMP® users showed a 15% increase in treatment adherence compared to those not using the device. Among children aged 5 to 12, the percentage of those taking their medication independently more than doubled, rising from 24% to 58% over three months. Meanwhile, parental involvement in administering medication fell from 50% to 28%. Additionally, 90% of parents reported feeling reassured by the device, with half saying they felt completely at ease managing treatment—up from 36% in the non-iPUMP® group.
Developed in partnership with Stallergenes Greer, iPUMP® is a digital tool designed to support personalized SLIT by helping patients adhere to prescribed dosage, frequency, and duration. The device syncs with a mobile app to provide access to individual treatment plans and includes a tracking feature for medication monitoring. Since its launch in France in February 2023, iPUMP® has been used by over 9,000 patients.
“The SPEED survey findings underscore the importance of connected health tools in boosting treatment adherence and patient confidence,” said Elena Rizova, Chief Medical Officer at Stallergenes Greer. “iPUMP® directly addresses the needs of both patients and healthcare professionals.”
Marcus Bates, Vice President of Business Development at Aptar Digital Health, added, “These results pave the way for broader adoption of digital solutions in allergy care, enabling better engagement and improved health outcomes.”
The survey strengthens Aptar’s and Stallergenes Greer’s commitment to advancing personalized, patient-centered digital health innovations in allergy treatment.
